Incyte (INCY) announces positive topline results from pivotal study of Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma
Importance
Level 1
#INCYTE CORP LTD#INCY.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#INCYTE CORP#INCY#US EQUITIES